# A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

> **NCT06742892** · PHASE2 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 90 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** HLX43 DOSE 1
- **DRUG:** HLX43 DOSE 2
- **DRUG:** HLX43 DOSE 3

## Key facts

- **NCT ID:** NCT06742892
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-06-05
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06742892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06742892, "A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06742892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*